CLARITHROMYCIN GRANULES FOR SUSPENSION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

CLARITHROMYCIN

থেকে পাওয়া:

SANIS HEALTH INC

এটিসি কোড:

J01FA09

INN (আন্তর্জাতিক নাম):

CLARITHROMYCIN

ডোজ:

125MG

ফার্মাসিউটিকাল ফর্ম:

GRANULES FOR SUSPENSION

রচনা:

CLARITHROMYCIN 125MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

55/105ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

OTHER MACROLIDES

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0123752003; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2013-07-26

পণ্য বৈশিষ্ট্য

_Product Monograph Master Template _
_Template Date: September 2020 _
_Pr_
_CLARITHROMYCIN - clarithromycin _
_Page 1 of 72_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
CLARITHROMYCIN
clarithromycin for oral suspension
Suspension, 125 mg/5 mL and 250 mg/5 mL when reconstituted, Oral
USP
Antibiotic
NOTE: WHEN USED IN COMBINATION WITH ACID ANTISECRETORY DRUGS AND OTHER
ANTIMICROBIALS FOR THE ERADICATION OF HELICOBACTER PYLORI, THE PRODUCT
MONOGRAPH
FOR THOSE AGENTS SHOULD BE CONSULTED.
SANIS HEALTH INC.
1 President's Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Initial Authorization:
July 26, 2013
Date of Revision:
February 18, 2022
Submission Control Number: 261133
_ _
_Product Monograph Master Template _
_Template Date: September 2020 _
_Pr_
_CLARITHROMYCIN - clarithromycin _
_Page 2 of 72_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
02/2022
7 WARNINGS AND PRECAUTIONS; 7.1.1 Pregnant Women; 7.1.2
Breast-feeding
02/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
..............................................................................................................
5
1.1
Pediatrics
...................................................................................................................
5
1.2
Geriatrics
...................................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
6
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 7
4